Figure 6.

Infiltration of CCR2⁺/CX3CR1⁺ cells into the glioma is reduced upon combination targeting of CCL2 and CCL7. (A) Treatment schematic for targeting CCL2 and CCL7 in KR158B or KR158B CCL7 KD gliomas. Anti-CCL2 antibody loading dose of 100μg was administered 3 days post implantation (DPI). Subsequent maintenance doses of 50μg were administered twice weekly. Non-immune IgG was used as a control. A total of 4 arms were evaluated: KR158B treated with IgG control, KR158B CCL7 KD treated with IgG control, KR158B treated with anti-CCL2 antibody, and KR158B CCL7 KD treated with anti-CCL2 antibody. (B) Graph depicting percentage of infiltrating live, CD45⁺, CD11b⁺, CCR2⁺ only cells within the tumor. (C) live, CD45⁺, CD11b⁺, CCR2⁺/CX3CR1⁺ cells within the tumor (D) live, CD45⁺, CD11b⁺, CX3CR1⁺ only cells within the tumor. (E) Representative flow plot for panels B-D depicting reduction of CCR2⁺/CX3CR1⁺ population within the tumor (n=5-6 per arm). Example gating strategy can be found in Supplementary Figure 11A . Two-way ANOVA statistical analysis was conducted (Dunnett’s multiple comparisons test). Differences are compared to the control condition or between cell lines. p-values: 0.0332(*), 0.0021(**), 0.0002(***).